The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Further information on the MOU
The MOU between Ananda, DJT and NTU will commence from 1 November 2023.
Ananda and DJT will bring to the partnership their collective proprietary background IP, expertise, methods, protocols, cannabis seed inventory and data to allow the recommencement of the genetics stabilisation programme. The Group will also provide the use of the existing research facility in Lincolnshire, if and when required.
NTU will provide its research capability and expertise, and work with Ananda and DJT through its grant capture team to pursue grant funding for the Partnership, including the drafting and submission of grant applications.
Ananda, DJT and NTU will form the first stage of the Strategic Partnership by seeking third-party funding for collaborative Knowledge Transfer Partnership projects, with a vision to establish a Cannabinoid Centre of Excellence at NTU based on the respective know-how of the parties.
The Cannabinoid Centre of Excellence will aim to add significantly to the scientific body of knowledge in the UK regarding medicinal cannabis, its cultivation, breeding and genetics, and its use to treat various human health conditions. It will aim to become a world leading Centre in this area by activity and reputation.
As part of the aim to establish a Cannabinoid Centre of Excellence, Ananda, DJT and NTU have also agreed to collaborate on the development of a broader pipeline of research and to seek grant funding for these additional research projects.
The MOU does not transfer ownership over any of the IP or proprietary information that Ananda and DJT and NTU separately, have developed to date. Ownership of any IP developed through the Strategic Partnership will be determined by negotiation between the parties as the MOU progresses to formal agreements.
Nottingham Trent University
NTU is an educational institute undertaking research & innovation from fundamental discovery to delivery of, technology and knowledge transfer. With over 40,000 students across five university sites, it is one of the largest and most influential higher education institutions in the country. NTU's expertise ranges from disciplines in Plant Genomics, Plant Breeding, Plant Active Ingredients Chemistry and Sustainability for ESG and SDG compliance, through to wider Talent Attraction & Retention and Executive Development support. Further information on NTU is available at https://www.ntu.ac.uk.
We can also develop the medical cannabis cultivation and manufacturing proposition around its sustainability credentials to seek significant grant funding for this business.
"The two years of genetics research and scaled cultivation trials we have undertaken at our Lincolnshire site have put us in a position to form this partnership, allowing us to take our hard-won proprietary knowledge through to commercialisation at a lower cost than previously envisaged.
"With patient numbers in the United Kingdom now around 30,000 and increasing month on month, this partnership will allow us to continue to build our skills and intellectual property to ensure we are ready to take advantage of commercial opportunities when market trends permit, without incurring the significant monthly costs being incurred under the previous strategy. We look forward to updating shareholders as we secure grant funding with our new partners."
Prof Richard Emes, Pro-Vice Chancellor of Research & Innovation said: "We are delighted to be partnering our research expertise with Ananda and DJT. Our research scientists look forward to being part of this very important journey to develop products that will positively change the lives of so many people."
Ananda Developments Plc Share Regulatory News
MOU signed with Nottingham Trent University
Today 07:00
RNS Number : 9287R
Ananda Developments PLC
ANANDA DEVELOPMENTS PLC
("Ananda", the "Company" or the "Group")
MOU signed with Nottingham Trent University
Ananda Developments plc (AQSE: ANA) and its wholly owned subsidiary DJT Plants Limited ("DJT") have signed a Memorandum of Understanding ("MOU") with Nottingham Trent University ("NTU") to pursue third-party grant funding to progress DJT's medical cannabis breeding programme and its low carbon medical cannabis cultivation and manufacturing. The shared vision, beyond the MOU, is to create a formal Strategic Partnership and the establishment of a Cannabinoid Centre of Excellence at NTU.
Highlights
· Ananda, DJT and NTU will combine their expertise and resources to pursue third-party grant funding to progress DJT's breeding and genetics programme as well as its low carbon cannabis cultivation and manufacturing.
· NTU's expertise includes Dr Gareth Cave who has previously conducted research into medical cannabis and has held a Schedule One Home Office licence to cultivate and research cannabis produced products, and Dr Chungui Lu, Professor in Sustainable Agriculture specialising in plant genomics and plant molecular biology.
· The initial focus will be to build on the success of the genetics and breeding programme and on packaging DJT's low carbon cultivation into a wider pharmaceutical innovation project to attract major grant funding.
· The shared vision, beyond the MOU, is to create a formal Strategic Partnership and the establishment of a Cannabinoid Centre of Excellence at NTU.
Ananda's CEO, Melissa Sturgess commented: "By partnering with NTU we can progress our breeding and genetics programme with the aid of non-dilutionary funding and with the additional resources and expertise of NTU.
What an excellent MOU update that is!
Well that's a solid informative update id say and right on the brink of a whole new chapter for the company in respect of the two nhs trials and more rcts to bolster the future and multiple applications of our formulas and the chance of full scale nhs adoption! Jeeez what would that do to the sp? Phase II trials for a micro cap are outstanding and to a impressive budget!
" The principals are not ripping pi off and Melissa Sturgess and Charles Morgan have invested between £3-4M of their own money in the company." yes thats why i thought it was a sound co but oh how wrong can i be ,surprised they haven t done a consolidation then a share issue ,that would be normal for life style co get the pi to invest then clever bookwork with the funds ,but of course to some thats an insult apparently
Want actually wasn't actually referring to you but nice to see I've touched a nerve. Perhaps work on your grammar too.
The company is moving in the right direction and as with all medical research it will be a long time before profits will be realised. The principals are not ripping pi off and Melissa Sturgess and Charles Morgan have invested between £3-4M of their own money in the company.
Brucebanner ,just what i expected from you ,what part was an insult ,only to those who cant handle the truth , you havent a clue who you are talking to ,ditto, keep your insults to yourself,and you cant tell me your strategy is brilliant if you are on here ramping if you think insults !! to a post and had to reply
Judging from page one of your posting history you don't have much luck anywhere, maybe it's time to give up insults and concentrate on your investment strategy.
Looks like i have been sucked in by another lifestyle co, 1p when i bought ,squeeze the pot payback the bod with bonuses ,the pi can go fry , same as deltic, ctea, msg , apparently legal but so transparent , kiss go bye to another 1k ,i must do better , i must do better , i must do better , mind you this recession by stealth most good shares are still floundering at mid covid prices ,lloyds , vodafone ,l and g ,capita,, time to stop day trading that will pi55 off the skimmers and perhaps we can start to build again
Will ANA come good?
I am still rather hopeful.
Sweet Jesus, Gaz, she's trying to help us. You really have gone from being a decent chap to little more than a child having a troll-sized tantrum.
The strange irony is that you must believe this company has something to offer because, despite your rants and sulks, you hang about. Anyone else would sell up and not waste time on something they didn't believe would do what it said it could.
You're your own red flag.
What a sad, bitter and utterly ungrateful individual you are. Melissa comes in here to answer questions and offer information and all you can do is moan and complain.
If you are so dissatisfied with the performance of the board of Ananda how about you just sell up.
That's great, thanks for that, Melissa.
For CIPN: The pre-clinical work is being done at the moment.
When the trial starts: Two periods of investigational medicinal product (IMP), each consisting of 5 weeks of treatment, will be separated by a 2-week wash-out period (ie taking nothing). So half the participants will do placebo then MRX1 and half will do do MRX1 then placebo. They won't know which group they are in.
For endometriosis: much of the pre-clinical trial work for CIPN will be able to be used for this trial.
100 women with pelvic pain due to endometriosis will be part of the trial. The women will be randomly assigned to take an oral cannabinoid called cannabidiol (MRX1 CBD) in a tincture (liquid) or identical placebo for twelve weeks. Neither the women, nor their medical team, will know what treatment they are taking.
Hi Melissa, are you able to say how long the clinical trials will last for in each case? I take it you are targeting different conditions? Thanks.
Thanks very much. :)
For us to have two phase II rct's on the go!
This is a massive achievement for a small cap!
We are presenting at the Investival Showcase at Old Billingsgate on the 13th November. This is effectively the 'small cap' day ahead of the big Jefferies Healthcare Conference, which we will be attending for networking. We are also presenting at the Aquis Showcase day on 28th November at the Royal College of Surgeons in WC2A. If anyone would like more information on either event please ping me on ms@anandadevelopments.com
Is doing, even. >_
Hello Melissa. Thanks for that.
Can you tell us what Ananda are going to be doing at the upcoming November conference, please? If indeed you are taking part as I recall reading somewhere.
There is lots of anecdotal 'evidence' for both THC and CBD and an increasing amount of science showing the anti inflammatory properties of CBD. Many of the conditions being treated by cannabis medicines have a large component of inflammation in them (fibromyalgia, chronic pain, endometriosis, rheumatoid conditions, depression, neuralgias to name a few) and given the psychoactive effects of THC it would be much easier to get wider acceptance of cannabis medicines if they don't always need THC. NICE (NHS research division) has specifically called for evidence (clinical trials) using CBD for this reason. So it seems clear that cannabis medicines are here to stay, it is a matter of getting the right evidence in the right format to get the regulator to support the prescribing and funding. CBD is a really good place to start because NICE has asked for the research, is prepared to fund it and it removes the 'debate' about the psychoactive concerns about THC.
In simple terms it's not all about the thc you see its very much about the cbd making it as clear as abc so no need to get on your high horse without giving you a pasting if you copy me